Nkarta, Inc.

Nkarta (NASDAQ: NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety. The company is developing an allogeneic, off-the-shelf CD19-targeted CAR natural killer, or CAR NK, cell therapy for autoimmune diseases. President Nadir

Nkarta, Inc. (NASDAQ: NKTX - Get Free Report)'s stock price fell 3.5% during trading on Friday. The stock traded as low as $2.73 and last traded at $2.75. 681,083 shares were traded during trading, an increase of 13% from the average daily volume of 600,515 shares. The stock had previously closed at $2.85. Wall Street Analyst

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: September 16, 2026 H.C.

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its selection for three scientific presentations at ACR Convergence 2026 being held November 6-11 in Orlando.